ENTRY       D06409                      Drug
NAME        Bevacizumab (USAN);
            Bevacizumab (genetical recombination) (JAN);
            Bevacizumab (genetical recombination) [Bevacizumab biosimilar 1] (JAN);
            Bevacizumab (genetical recombination) [Bevacizumab biosimilar 2] (JAN);
            Bevacizumab (genetical recombination) [Bevacizumab biosimilar 3] (JAN);
            Bevacizumab (genetical recombination) [Bevacizumab biosimilar 4] (JAN);
            Bevacizumab-awwb;
            Bevacizumab-bvzr;
            Bevacizumab-maly;
            Bevacizumab-adcd;
            Avastin (TN);
            Alymsys (TN);
            Mvasi (TN);
            Vegzelma (TN);
            Zirabev (TN)
PRODUCT     ALYMSYS (Amneal Pharmaceuticals LLC)
            AVASTIN (Genentech)
            MVASI (Amgen)
            VEGZELMA (CELLTRION USA)
            ZIRABEV (Pfizer Laboratories Div Pfizer)
FORMULA     C6638H10160N1720O2108S44
EXACT_MASS  149104.8407
MOL_WEIGHT  149196.8162
REMARK      Therapeutic category: 4291
            ATC code: L01FG01 S01LA08
            Product: D06409<JP/US>
EFFICACY    Antineoplastic, Angiogenesis inhibitor, Anti-VEGF antibody
  DISEASE   Colorectal cancer [DS:H00020]
            Non-squamous non-small cell lung cancer [DS:H00014]
            Glioblastoma [DS:H00042]
            Renal cell carcinoma [DS:H00021]
            Cervical cancer [DS:H00030]
            Epithelial ovarian cancer [DS:H00027]
            Fallopian tube cancer [DS:H01554]
            Primary peritoneal cancer [DS:H01665]
            Hepatocellular carcinoma [DS:H00048]
  TYPE      Monoclonal antibody
TARGET      VEGFA [HSA:7422] [KO:K05448]
  PATHWAY   hsa04370(7422)  VEGF signaling pathway
            hsa05200(7422)  Pathways in cancer
            hsa05211(7422)  Renal cell carcinoma
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
                 L01FG01 Bevacizumab
                  D06409  Bevacizumab (USAN) &lt;JP/US&gt;
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA08 Bevacizumab
                  D06409  Bevacizumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Bevacizumab
                D06409  Bevacizumab (USAN)
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Vascular Endothelial Growth Factor (VEGF) Inhibitor
                Bevacizumab
                 D06409  Bevacizumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D06409  Bevacizumab (USAN); Bevacizumab (genetical recombination) (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 1] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 2] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 3] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 4] (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D06409  Bevacizumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06409
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06409
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06409
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06409
DBLINKS     CAS: 216974-75-3
            PubChem: 47208066
            NIKKAJI: J2.239.973J
///
